Tirzepatide: Primary completion of P3 SURMOUNTADOLESCENTS-2 trial (NCT06439277) in adolescents with obesity and weight-related comorbidities in May 2027 (Eli Lilly) - Oct 30, 2024 - Q3 2024 Results: Completion of P3 SURMOUNT-ADOLESCENTS-2 trial in adolescents with obesity and weight-related comorbidities in Jun 2027; Primary completion and completion of P3 SURMOUNT-MMO trial (NCT05556512) in adults with obesity in Oct 2027
Trial completion date • Trial primary completion date • Metabolic Disorders • Obesity
|